

Patients achieved
early platelet **Boost**
with **Romiplate**^{®1*}

Fast onset of action

- ▶ Median time to platelet response was 2.1 weeks¹
- ▶ 88% of patients achieved a platelet response^{2#}

Sustained Response

- ▶ 61% of patients sustained platelet counts $\geq 50 \times 10^9/L$ for ≥ 11 months during the treatment period¹



Abbreviated Package Insert of ROMIPLATE Power for Solution for Injection 250mcg

Composition: Romiplostim. **Indications:** Adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) in splenectomized patients who are refractory to other treatments (e.g. corticosteroids & immunoglobulins); 2nd-line treatment for adult non-splenectomized patients where surgery is contraindicated. **Dosage and Administration:** SC inj Initially 1 mcg/kg (ABW) q1w, may be increased by increments of 1 mcg/kg until achieving a PLC $\geq 50 \times 10^9/L$. Max: 10 mcg/kg q1w. **Contraindications:** Hypersensitivity to romiplostim or any of the excipients or E. coli-derived proteins. **Precautions:** Recurrence of thrombocytopenia & bleeding after discontinuation. Increased bone marrow reticulin. Thrombotic/thromboembolic complications. Progression of existing myelodysplastic syndrome (MDS). Immunogenicity. Alterations in RBC & WBC. Renal & hepatic impairment. May impair ability to drive or operate machinery. Pregnancy & lactation. Child <18 yr. **Common adverse reactions:** Hypersensitivity reactions, Headache. **Serious adverse reactions:** recurrence of thrombocytopenia and bleeding after cessation of treatment, increased bone marrow reticulin, thrombotic/thromboembolic complications, progression of existing MDS to AML. **P/P:** Powder for soln for inj (vial) 250 mcg x 1s. Approved version of package insert: Sep 2019.

Please refer to the full prescribing information before prescribing. Further information is available upon request.

* Platelet response was defined as a platelet count $\geq 50 \times 10^9/L$ # Based on Overall Platelet Response in non-splenectomized patient

Reference: 1. Newland A, Godeau VP, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. *Br J Haematol.* 2016;172(2):262-273. 2. Vishnu P, Aboutafia DM. Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. *J Blood Med.* 2016;7:99-106. 3. Hong Kong Prescribing Information, Sep 2019.

THIS MATERIAL IS MEANT FOR HEALTHCARE PROFESSIONALS ONLY